Casa
o que significa a fórmula y=c+i+g+(x-m)

The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3

Por um escritor misterioso

Descrição
IMR Press is a leading publisher of open access peer-reviewed biomedical and life sciences journals. We aim to facilitate the dissemination of high-quality research in the area of biomedical science. With a long tradition and wide readership, IMR Press is dedicated to making positive contributions to academics, corporate libraries as well as to readers and authors. All the editors in IMR Press will provide the best service for researchers, allowing them to have a easy and smooth publication experience and helping maximize the impact and visibility of their research.
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Cardiorenal syndrome: Multi‐organ dysfunction involving the heart
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Cardiorenal Syndrome Revisited
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Kidney and heart interactions during cardiorenal syndrome: a
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Advances in pathogenesis and current therapeutic strategies for
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Anemia of cardiorenal syndrome - Kidney International Supplements
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Frontiers A comprehensive review of acute cardio-renal syndrome
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Cardio renal syndrome - Cancer Therapy Advisor
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Cardiorenal syndrome—current understanding and future perspectives
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Cardiorenal Syndrome Journal of the American College of Cardiology
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Cardiorenal protection of SGLT2 inhibitors—Perspectives from
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3
Cardiac Spinal Afferent Denervation Attenuates Renal Dysfunction
de por adulto (o preço varia de acordo com o tamanho do grupo)